{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:48:34Z","timestamp":1787676514986,"version":"build-2784847793"},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.clml.2024.04.002","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T02:39:04Z","timestamp":1712716744000},"page":"553-563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Burden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell Malignancy"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Anderson-Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9931-2228","authenticated-orcid":false,"given":"Marta","family":"Kamieniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3323-3553","authenticated-orcid":false,"given":"Kaili","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7886-6088","authenticated-orcid":false,"given":"Jasjit K.","family":"Multani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5866-7743","authenticated-orcid":false,"given":"Drishti","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba","family":"Siffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.04.002_bib0001","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3389\/fimmu.2019.00586","article-title":"Primary and secondary immunodeficiency diseases in oncohaematology: warning signs, diagnosis, and management","volume":"10","author":"Sanchez-Ramon","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2024.04.002_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.101020","article-title":"Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: recommendations from an international expert panel","volume":"58","author":"Jolles","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2024.04.002_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1098326","article-title":"Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: a systematic literature review","volume":"13","author":"Jolles","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2024.04.002_bib0004","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2024.04.002_bib0005","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/ejh.13223","article-title":"Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies","volume":"102","author":"Na","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2024.04.002_bib0006","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","article-title":"The expanding field of secondary antibody deficiency: causes, diagnosis, and management","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2024.04.002_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107365","article-title":"Management of humoral secondary immunodeficiency in hematological malignancies and following hematopoietic stem cell transplantation: regional perspectives","author":"Ar","year":"2023","journal-title":"Leuk. Res."},{"key":"10.1016\/j.clml.2024.04.002_bib0008","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41408-021-00532-1","article-title":"Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.04.002_bib0009","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.14785","article-title":"Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study","volume":"178","author":"Strati","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.04.002_bib0010","doi-asserted-by":"crossref","first-page":"e499","DOI":"10.1038\/bcj.2016.105","article-title":"Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients","volume":"6","author":"da Cunha-Bang","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.04.002_bib0011","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002\u2013Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.04.002_bib0012","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-018-0068-5","article-title":"A systematic classification of death causes in multiple myeloma","volume":"8","author":"Mai","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.04.002_bib0013","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.04.002_bib0014","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/ejh.13264","article-title":"Understanding mortality in multiple myeloma: findings of a European retrospective chart review","volume":"103","author":"Mohty","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2024.04.002_bib0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12885-023-10787-5","article-title":"Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany","volume":"23","author":"Eisfeld","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2024.04.002_bib0016","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/ejh.13580","article-title":"Treating secondary antibody deficiency in patients with haematological malignancy: european expert consensus","volume":"106","author":"Jolles","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2024.04.002_bib0017","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clml.2024.04.002_bib0018","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1080\/10428194.2021.1961233","article-title":"Infections in secondary immunodeficiency patients treated with Privigen\u00ae or Hizentra\u00ae: a retrospective US administrative claims study in patients with hematological malignancies","volume":"62","author":"Mallick","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.04.002_bib0019","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2217\/imt-2022-0142","article-title":"Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infections","volume":"14","author":"Lahue","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.clml.2024.04.002_bib0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/ejh.13078","article-title":"A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency","volume":"101","author":"Benbrahim","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2024.04.002_bib0021","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.930241","article-title":"Secondary immunodeficiency and hypogammaglobulinemia with igg levels of <5 g\/l in patients with multiple myeloma: a retrospective study between 2012 and 2020 at a university hospital in China","volume":"27","author":"Ye","year":"2021","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.clml.2024.04.002_bib0022","unstructured":"European Medicines Agency. Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) 2021 [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-core-smpc-human-normal-immunoglobulin-intravenous-administration-ivig-rev-6_en.pdf accessed February 2, 2024."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T11:47:25Z","timestamp":1729856845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024001502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2152265024001502"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.04.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell Malignancy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}